

Elenco Oral Posters

ID	Title	Presenting Author
Antiretroviral Therapy		
188	OP 1 Evaluation of total HIV-DNA and residual viremia in HIV-1 infected patients who continue a two-drug regimen with dolutegravir plus one reverse transcriptase inhibitor or switch to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide enrolled in the Be-OnE Study	Maria Santoro, Roma
268	OP 2 Durability and liver safety of InSTI-based regimens in HIV-infected patients with advanced liver fibrosis or cirrhosis: data from the ODOACRE cohort	Alessandro Lanari, Siena
281	OP 3 Prevalence of transmitted resistance mutations to rilpivirine and doravirine in treatment-naïve patients in a large clinical and resistance database	Francesca Lombardi, Roma
117	OP 4 Efficacy and tolerability of bictegravir/ tenofovir alafenamide/ emtricitabine as a switch strategy in a cohort of antiretroviral therapy treatment-experienced HIV-1-infected patients	Filippo Lagi, Firenze
163	OP 5 Viral rebound in pts with suppressed HIV-RNA on a 2 or 3-drug regimen: a comparison	Alberto Borghetti, Roma
191	OP 6 Optically traceable PLGA Nanoparticles improve the ability of darunavir to cross the blood brain barrier and inhibit MMP-9. Implications for the Treatment of HIV-Associated Neurological Disorders	Serafina Milella, Bari
199	OP 7 Effectiveness and long-term durability of rilpivirine-based single tablet regimens in a large cohort of HIV-infected patients. A preliminary analysis	Rachele Pincino, Genova
5	OP 8 Increase in body weight after a year of INI-exposure in a multicenter italian cohort	Arturo Ciccullo, Roma
226	OP 9 Treatment outcome among HIV-1 infected patients who started first-line ART pending GRT results from 2015 to 2018	Davide Fiore Bavaro, Bari
92	OP 10 Retrospective analysis of reasons and characteristics of switches in a cohort of women affected by HIV infection referring to "D. Cotugno" Hospital, Naples, period 2017-2019	Francesco Maria Fusco, Napoli
217	OP 11 Assessing the feasibility of 2-drug regimens as switch strategies in a multicenter cohort	Arturo Ciccullo, Roma
95	OP 12 Risk of failure in dual vs triple therapy in naïve HIV-patients: a meta-analysis	Antonio Russo, Caserta
Basic science and immunology		
309	OP 13 DAA treatment fails to restore the inflammatory profile both in HCV/HIV and in HCV infected patients	Chiara Agrati, Roma
79	OP 14 Sterol metabolism modulates susceptibility to HIV-1 Infection	Irma Saulle, Milano
270	OP 15 Different amounts of activated or exhausted effector memory T cells among differentiated CD4+ or CD8+ T lymphocytes during primary, acute HIV infection	Andrea Cossarizza, Modena
277	OP 16 HIV+ patients: modulating effects of antiretroviral therapy on cytokines' profile and microbiota composition	Giulia Nannini, Firenze
352	OP 17 Association between subclinical atherosclerosis and IFN-I response in HIV-1 infected patients	Gabriella De Girolamo, Roma
263	OP 18 p53/mir34a/SIRT1 loop and immune reconstitution relationship during chronic HIV infection	Veronica Bordoni, Roma
19	OP 19 Lower Immune Activation in Perinatally than in Horizontally HIV-Infected Adults	Lucia Taramasso, Milano
151	OP 20 Microbiota Composition in HIV-Positive and HIV-Exposed Uninfected Pediatric Subjects	Stefania Cannizzo, Milano
18	OP 21 Switching to integrase inhibitors is not linked to weight increase in young adults and adolescents perinatally infected with HIV, results from a 10-years observational study	Lucia Taramasso, Milano
143	OP 22 An atypical case of HIV-1 elite controller: 15 years of follow up	Caterina Fimiani, Roma
Clinical HIV		
276	OP 23 Newly diagnosed HIV infected patients in Brescia, Northern Italy: epidemiological and clinical characteristics and possible targets of prevention and early diagnosis campaign	Gianluca Zuglian, Brescia
16	OP 24 Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in HIV-infected patients with metabolic syndrome	Leonardo Calza, Bologna
275	OP 25 Durability of InSTI-based regimen in geriatric people living with HIV. Data from the Italian Multicenter GEPPCO Cohort	Emanuele Focà, Brescia

Elenco Oral Posters

ID	Title	Presenting Author
206	OP 26 Weight gain and body composition changes in people living with HIV treated with Integrase Strand Transfer Inhibitors: a longitudinal assessment with Bioimpedance Vectorial Analysis	Mariacristina Polisenno, Bari
189	OP 27 Transmitted drug resistance in newly diagnosed HIV-1-infected patients in a large teaching hospital of the Northern Italy	Leonardo Calza, Bologna
28	OP 28 Same day treatment and rapid antiretroviral therapy introduction in a cohort of unselected newly-diagnosed HIV-positive individuals	Giuseppe Lapadula, Monza
250	OP 29 Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression	Camilla Muccini, Milano
59	OP 30 A descriptive analysis on dual regimens' discontinuations in a multicentre Italian cohort	Damiano Farinacci, Roma
346	OP 31 Virological response and resistance profile in highly treatment-experienced HIV-1 infected patients switching to dolutegravir plus boosted-darunavir in clinical practice	Daniele Armenia, Roma
295	OP 32 Does rapid initiation of ART at HIV diagnosis impact on virological response and retention in care? A single center experience (Brescia, Northern Italy)	Natalia Gregori, Brescia
264	OP 33 Efficacy and durability of dolutegravir- or darunavir-based regimens in ART-naïve AIDS- or late-presenter patients	Melissa Masini, Siena
259	OP 34 Efficacy Safety and Tolerability of the switch from efavirenz/emtricitabine/tenofovir disoproxil on alternate days or continuous treatment to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed HIV+ (EBONY Study)	Marta Camici, Roma
Clinical HIV II		
56	OP 35 Allogenic hematopoietic stem cell transplantation in HIV-positive recipients: a case series	Chiara Oltolini, Milano
71	OP 36 Italian survey on clinicians' approach to Latent Tubercular Infection in people living with HIV	Luca Caiazzo, Chieti
177	OP 37 A poor immunological recovery is associated with non-AIDS-defining cancers in the era of HAART: a case-control study	Arianna Emiliozzi, Siena
216	OP 38 HPV infection in HIV+, MSM patients followed at a large HIV Clinic in Northern Italy	Erika Asperges, Pavia
335	OP 39 Risk of multiple primary neoplasms and impact on survival of person living with HIV (PLWH)	Valentina Mazzotta, Roma
68	OP 40 Development and standardization of a real time PCR for the quantification of HTLV-1 proviral load	Alessandra Primavera, Bologna
35	OP 41 Is pretreatment HIV-1 integrase resistance increasing? A large Italian centre experience	Diana Canetti, Milano
252	OP 42 Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection	Camilla Muccini, Milano
119	OP 43 Evolving epidemiology of HIV/AIDS in Campania Region, 2008-19: is HIV/AIDS population in Campania different?	Francesco Maria Fusco, Napoli
324	OP 44 Impact of boosted vs unboosted antiretroviral regimen on Dolutegravir plasma and intracellular pharmacokinetics	Micol Ferrara, Torino
Comorbidities		
51	OP 45 Inflammatory and neurometabolite changes among patients switching away from efavirenz and their correlation with neurotoxicity: results from the sub-study of a randomized controlled trial	Giuseppe Lapadula, Monza
120	OP 46 Contribution of INSTI, BMI, physical activity or caloric intake to weight gain in PLWH	Giovanni Dolci, Modena
137	OP 47 Cerebrospinal Fluid CXCL13 as a marker of Intrathecal Immunoglobulin Synthesis and Immune-activation in treatment-naïve People Living with HIV	Mattia Trunfio, Torino
287	OP 48 Evaluation of the association between cognitive performance and HAND diagnosis with the cognitive reserve in naïve HIV-infected patients	Anna Clelia Brita, Roma
234	OP 49 Are Low vitamin D plasma levels associated with intrathecal immuneactivation in PLWH?	Alessandra Vergori, Roma
175	OP 50 Gender differences in neurocognitive functions in PLWH	Valentina Delle Donne, Roma
246	OP 51 Menopause in aging women living with HIV: changes in bone mineral density and trabecular bone score	Denise Morini, Modena

Elenco Oral Posters

ID	Title	Presenting Author
230	OP 52 NAFLD phenotype and prevalence across the menopause spectrum in women with HIV	Jovana Milic, Modena
84	OP 53 Incidence of diabetes in a cohort of PLWH people living with HIV in Perugia	Elisabetta Schiaroli, Perugia
203	OP 54 Standard vs higher dose of Rifampicin in patients with tuberculosis: a meta-analysis	Valeria Gentile, Caserta
Hepatitis and coinfections		
179	OP 55 Rapid Detection of Mycobacterium tuberculosis DNA in pulmonary and extrapulmonary paraffinized samples by ddPCR	Maria Antonello, Milano
153	OP 56 Pharyngeal contamination is a major driver for sexually transmitted infections epidemic in Men who have Sex with Men	Roberto Rossotti, Milano
97	OP 57 HCV infection in PWUD: a microelimination intervention in Rome	Chiara Taibi, Roma
98	OP 58 Direct-acting antiviral based treatment for HCV-infected persons who inject drugs: a multi-centre real-life study	Lorenzo Onorato, Napoli
322	OP 59 Are Non-Injecting Drug Users at risk of HCV-infection? Data from the San Patrignano cohort	Antonio Boschini, Coriano RN
187	OP 60 Real Life DAAs in a large cohort of people who use drugs with hepatitis C virus infection in Tor Vergata Hospital in Rome: adherence, efficacy and reinfections of a key population	Tiziana Mulas, Roma
342	OP 61 Effects of HCV eradication on liver function in haemophilic HIV/HCV co-infected patients	Valeria Castelli, Milano
248	OP 62 Virological patterns of HCV-patients with failure to second generation direct-acting antivirals	Mario Starace, Napoli
47	OP 63 Advanced liver disease outcomes after Hepatitis C viral eradication according to Human Immunodeficiency Virus coinfection in PITER cohort	Maria Giovanna Quaranta, Roma
312	OP 64 The combination of accurate serological and virological HBV markers can help to predict the occurrence of HBV reactivation and to optimize prophylaxis duration in HBsAg-negative/anti-HBc-positive patients with oncohematological diseases	Mohammad Alkhatib, Roma
134	OP 65 HBV and HDV infection in immigrants living in South Italy: epidemiological and virological characteristics	Lorenzo Onorato, Napoli
130	OP 66 HEV infection as an emergent public health issue: is it a concern for Italian blood donors?	Luna Colagrossi, Milano
Social Science and prevention		
104	OP 67 HIV SelfTesting: a survey of self-tests availability in Italian Pharmacies	Manuel Maffeo, Milano
106	OP 68 Testing MSM in cruising venues	Donatello Zagato, Milano
370	OP 69 Behavioral aspects of MSM tested in community-based settings in 5 cities	Michele Breveglieri, Bologna
29	OP 70 Pre-exposure prophylaxis in Modena: a wide spread of sexually transmitted infections among users attending the dedicated outpatient Clinic	Carlotta Rogati, Modena
154	OP 71 Prevalence and risk factors for HPV anal infection in PrEP users: implications for vaccination policy	Roberto Rossotti, Milano
112	OP 72 NEETagers for the prevention of HIV and AIDS	Vanessa Corallino, Perugia
90	OP 73 Clinical research integrated with narrative medicine to understand living and coping with HIV: TMC114FD1HTX4011 - DIAMANTE study	Gian Carlo Orofino, Torino
292	OP 74 Women and HIV in prison setting: a data up date from the Italian ROSE network	Elena Rastrelli, Viterbo
166	OP 75 First-year experience of an HIV clinic-based stop-smoking service	Vincenzo Spagnuolo, Milano
148	OP 76 Psychiatric disturbances are common in PrEP users: an analysis of comorbidities and comedication in real life	Roberto Rossotti, Milano
Virology and pharmacology		
271	OP 77 The HIV-1 provirus excised by CRISPR/Cas9 may be integrated back into the cell genome in presence of the viral integrase	Michele Lai, Pisa
192	OP 78 Analysis of HIV latency establishment and maintenance in CD4 T cells stimulated with IL-15	Lara Manganaro, Milano
76	OP 79 Phylogenetic analyses applied to the study of transmission variants and their evolution in a HIV-1 positive couple	Claudio Fenizia, Milano

Elenco Oral Posters

ID	Title	Presenting Author
74	OP 80 Creation of an Italian HIV DNA Network for the validation and clinical use of HIV-1 DNA quantification assays	Ilaria Vicenti, Siena
63	OP 81 Initial characterization of elements detected and quantified exclusively on the basis of LTR region by Aptima HIV-1 Quant Dx dual-target assay in plasma of HIV-positive patients	Alessandra Amendola, Roma
208	OP 82 Stable total HIV-DNA after 1 year on switch to TAF-based regimens in real world data	Claudia Alteri, Milano
165	OP 83 HIV-1 RNA and DNA mutational load in HTE patients with MDR virus: a tool for deciding OBR?	Daniele Armenia, Roma
96	OP 84 Viral tropism does not have any impact on CD4 recovery in acute HIV infection or AIDS	Davide Vita, Milano
291	OP 85 Antiviral effect of HIV1 tat/rev siRNA carried by nanoparticles in human CD4+ T cell line	Francesca Falasca, Roma
344	OP 86 A real-life experience of vaccination strategies for HBV prevention in HIV patients	Daniele Tomasoni, Milano
235	OP 87 A successful experience of an immunization program in HIV-positive adults	Gabriella Chieffo, Busto Arsizio VA
64	OP 88 Plasma exchange and dolutegravir exposure. A case report	Marco Mussa, Alessandria